Abstract
We investigated whether the local intrathalamic infusion of a muscarinic acetylcholine receptor agonist (oxotremorine) at either the reticular nucleus of thalamus (NRT) or the ventroposteromedial nucleus of thalamus (VPM) suppresses thalamocortically generated neocortical high-voltage spindles (HVSs). In addition, we studied whether the intracerebroventricular (ICV) infusion of a selective muscarinic M2 acetylcholine receptor antagonist (methoctramine) could block the suppression of HVSs induced by either systemic (IP) administration of an anticholinesterase drug [tetrahydroaminoacridine (THA)] or ICV infusion of oxotremorine in rats. Intrathalamic administration of oxotremorine at 3 and 15 μg in the NRT, and at 15 μg in the VPM suppressed HVSs. ICV oxotremorine at 30 and 100 μg and IP THA at 3 mg/kg decreased HVSs. ICV methoctramine at 100 μg increased HVSs and completely blocked the decrease in HVSs produced by oxotremorine 100 μg and THA 3 mg/kg. The results suggest that activation of muscarinic M2 acetylcholine receptors in thalamic nuclei (NRT and VPM) can suppress thalamocortical oscillations and that ICV or systemically administered drugs that activate either directly (oxotremorine and methoctramine) or indirectly (THA) the muscarinic M2 acetylcholine receptors may modulate neocortical HVSs via the thalamus.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 13 November 1997/Final version: 18 April 1998
Rights and permissions
About this article
Cite this article
Puoliväli, J., Jäkälä, P., Koivisto, E. et al. Oxotremorine suppresses thalamocortical oscillations via thalamic muscarinic acetylcholine receptors. Psychopharmacology 140, 285–292 (1998). https://doi.org/10.1007/s002130050769
Issue Date:
DOI: https://doi.org/10.1007/s002130050769